免疫系统
单克隆抗体
癌症研究
免疫抑制
抑制器
炎症
跨膜蛋白
肿瘤微环境
免疫疗法
免疫学
封锁
肿瘤坏死因子α
生物
医学
细胞生物学
细胞毒性T细胞
抗体
免疫检查点
信号转导
移植排斥反应
细胞停滞
细胞因子
T细胞
巨噬细胞
靶向治疗
功能(生物学)
免疫耐受
作者
Xiaozhen Kang,Xiangmin Tong,Shibing Wang
标识
DOI:10.3389/fimmu.2026.1809305
摘要
Tumor necrosis factor (TNF) exerts paradoxical effects in cancer, driven by the differential engagement of its two receptors, TNFR1 and TNFR2. While TNFR1 mediates cytotoxic signaling, accumulating evidence indicates that TNFR2 predominantly orchestrates tumor-promoting inflammation and immunosuppression within the tumor microenvironment (TME). TNFR2 is highly expressed on regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), cancer-associated fibroblasts (CAFs), and malignant cells, forming a coordinated network that drives immune evasion and contributes to resistance to immune checkpoint blockade (ICB). In this review, we dissect the structural and functional distinctions between transmembrane and soluble TNF and discuss how these differences shape receptor-specific signaling outcomes. We further highlight emerging therapeutic strategies targeting the TNF-TNFR2 axis, including monoclonal antibodies, antibody-drug conjugates (ADCs), and bispecific antibodies, with an emphasis on their ability to selectively remodel the immunosuppressive TME. Finally, we discuss key challenges for clinical translation, including on-target toxicity, patient stratification, and context-dependent TNFR2 biology, and outline future directions such as biomarker-guided therapy and tumor-restricted targeting approaches. Together, these advances position TNFR2 as a promising therapeutic node for overcoming resistance to current immunotherapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI